Leptomeningeal metastasis: challenges in diagnosis and treatment
T Leal, JE Chang, M Mehta… - Current cancer therapy …, 2011 - ingentaconnect.com
As therapeutic options and supportive care for the treatment of neoplastic disease have
improved, there has been an associated increase in the incidence of leptomeningeal …
improved, there has been an associated increase in the incidence of leptomeningeal …
[HTML][HTML] Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%
M Reck, D Rodríguez-Abreu, AG Robinson… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell
Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% - PMC Back to Top Skip to main …
Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% - PMC Back to Top Skip to main …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
[HTML][HTML] Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Background Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has
shown clinical activity in pretreated patients with several tumor types, including colorectal …
shown clinical activity in pretreated patients with several tumor types, including colorectal …
NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 in: Journal of the
National Comprehensive Cancer Network Volume 19 Issue 3 (2021) Jump to Content User …
National Comprehensive Cancer Network Volume 19 Issue 3 (2021) Jump to Content User …
[HTML][HTML] Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and …
SV Liu, M Reck, AS Mansfield, T Mok… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE: IMpower133 (ClinicalTrials. gov identifier: NCT02763579), a randomized,
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed …
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed …
NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines
DS Ettinger, DE Wood, C Aggarwal, DL Aisner… - Journal of the National …, 2019 - jnccn.org
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of
management for NSCLC. These NCCN Guidelines Insights focus on recent updates in …
management for NSCLC. These NCCN Guidelines Insights focus on recent updates in …
NCCN guidelines insights: non–small cell lung cancer, version 5.2018
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of
management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the …
management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the …
[HTML][HTML] First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)
PURPOSE Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent
inhibitor of KRAS G12C. We report results from a phase I/IB study of adagrasib in non–small …
inhibitor of KRAS G12C. We report results from a phase I/IB study of adagrasib in non–small …
[HTML][HTML] Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
ES Kim, V Velcheti, T Mekhail, C Yun, SM Shagan… - Nature medicine, 2022 - nature.com
Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in
predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess …
predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess …